Rituxan (rituximab) - Roche
Stimufend (pegfilgrastim-fpgk) - Fresenius Kabi
Neupogen (filgrastim) - Kyowa Kirin, Amgen
betamethasone microsphere (DE-102) - Santen
doxorubicin hydrochloride - Generic mfg.
vincristine - Generic mfg.
prednisone delayed-release tablet - Generic mfg.
Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) - Jazz
Dulastin (tripegfilgrastim) - Dong-A
etoposide IV - Generic mfg.
cyclophosphamide - Generic mfg.
Neulasta (pegfilgrastim) - Roche
Mabtas (rituximab biosimilar) - Intas
Truxima (rituximab-abbs) - Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
daunorubicin - Generic mfg.
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 30, 2026 - P2 | N=30 | Suspended | Sponsor: University of Washington | Recruiting ➔ Suspended 
Trial suspension • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia
http://clinicaltrials.gov/ct2/show/NCT06738368
 
Sep 30, 2026
 
Prev Next